This is a routine post-annual meeting filing with no material trading implications. The ESPP share increase is standard and immaterial relative to market cap. Monitor for any future insider selling patterns following the board resignation, though the departure was explicitly non-disagreement.
Price Chart
Executive Summary
Spyre Therapeutics held its 2026 Annual Meeting on May 27, 2026, where stockholders approved the amended and restated 2016 Employee Stock Purchase Plan (AR ESPP), adding 1,056,096 shares to the reserve. Director Peter Harwin resigned effective the same date, with no disagreement cited, and the board was reduced from eight to seven members. This is a routine governance filing with no material financial impact.
Key Facts
- Stockholders approved the Amended and Restated 2016 Employee Stock Purchase Plan, adding 1,056,096 shares to the reserve.
- Director Peter Harwin resigned effective May 27, 2026, with no disagreement with the company.
- Board size reduced from eight to seven directors.
- All three Class I director nominees (Mark McKenna, Cameron Turtle, Laurie Stelzer) were elected.
- KPMG LLP was ratified as independent auditor for fiscal year 2026.
- Say-on-pay proposal received 92.7% support from votes cast (excluding broker non-votes).
Financial Impact
No financial figures reported. The AR ESPP adds 1,056,096 shares to the reserve, representing potential future dilution of approximately 0.7% based on the company's market cap of $6.3B, but no immediate financial impact.
Risk Factors
- Potential future dilution from the 1,056,096 ESPP share reserve, though minimal relative to current market cap.
- Board reduction from eight to seven may concentrate decision-making, but no immediate concern.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001636282-26-000056 |
| Document: syre-20260527.htm | 0001636282-26-000056 |
| Document: 0001636282-26-000056-index-headers.html | 0001636282-26-000056 |
| Document: 0001636282-26-000056-index.html | 0001636282-26-000056 |
| Document: 0001636282-26-000056.txt | 0001636282-26-000056 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 28d ago | Insider Cluster | $88.98 $90.80 | ▼ −2.05% | ▼ −3.25% | $93.19 (−4.73%) |
Aug 11, 2026 7w ago | Insider Cluster | $102.74 $107.82 | ▼ −4.94% | ▼ −5.35% | $93.19 (+9.30%) |
Aug 6, 2026 8w ago | Insider Cluster | $103.42 $101.85 | ▲ +1.52% | ▲ +2.73% | $93.19 (+9.89%) |
Jul 3, 2026 13w ago | Insider Cluster | $86.63 $98.75 | ▲ +13.99% | ▲ +13.06% | $93.19 (+7.57%) |
Jun 27, 2026 13w ago | Insider Cluster | $90.16 $88.74 | ▲ +1.57% | ▲ +2.96% | $93.19 (−3.36%) |
Jun 26, 2026 14w ago | S-3ASR | $90.16 $88.74 | ▼ −1.57% | ▼ −2.96% | $93.19 (+3.36%) |
Jun 24, 2026 14w ago | Insider Cluster | $86.24 $88.89 | ▼ −3.07% | ▼ −1.37% | $93.19 (−8.06%) |
Jun 15, 2026 15w ago | 8-K | $83.58 $100.32 | ▲ +20.03% | ▲ +21.41% | $93.19 (+11.50%) |
Jun 12, 2026 16w ago | Institutional Cluster | $80.79 $88.34 | ▲ +9.35% | ▲ +8.67% | $93.19 (+15.35%) |
Jun 11, 2026 16w ago | Institutional Cluster | $80.77 $87.49 | ▲ +8.32% | ▲ +7.89% | $93.19 (+15.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access